Peer-reviewed veterinary case report
Measuring QLNC-3A6 drug levels in dog blood for treatment studies
By Chen, Sumeng et al.·Published in The veterinary quarterly·2024·Department of Veterinary Pharmacology and Toxicology, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Determination of QLNC-3A6 in canine plasma by UHPLC-MS/MS and its application in pharmacokinetic studies.
- Species:
- dog
Plain-English summary
A study looked at a new medication called QLNC-3A6 Di-maleate, designed to treat skin tumors in dogs caused by specific genetic mutations. Researchers found that when dogs were given this medication, it was quickly absorbed into their bloodstream and stayed effective for a longer period. The medication showed promising results in terms of how well it was distributed and how long it remained in the dog's system. This information is important for veterinarians to understand how to use this treatment effectively for dogs with cutaneous mast cell tumors.
People also search for: dog skin tumor treatment · QLNC-3A6 for dogs · mast cell tumor medication for dogs
Abstract
Multi-targeted tyrosine kinase inhibitor QLNC-3A6 Di-maleate, a structurally novel small molecule compound, has therapeutic efficacy for the treatment of canine cutaneous mast cell tumor (CMCT) caused by mutations in the c-Kit gene. Since pharmacokinetic (PK) information plays an important role in the development and application of new drugs, etc., a rapid, highly sensitive and selective UHPLC-MS/MS analytical method was developed and validated for the first time in this study for the quantitative detection of QLNC-3A6 in canine plasma. 100 µL of plasma was precipitated using 350 µL of acetonitrile, and Chromatographic separation was performed on a Phenomenex Kinetex C18 column (50 × 2.1 mm, 2.6 µm) at a flow rate of 0.4 mL/min, the mobile phases were set to 0.1% formic acid aqueous solution (A) and 0.1% formic acid acetonitrile (B). The calibration curve linear range was 0.5-100 ng/mL (>0.99). The intraday and interday precision values (relative standard deviation, RSD) were 2.06-13.57% and 6.90-9.14%. Intraday and interday accuracies were -10.73 to 9.54% and -3.86 to 0.70% respectively. The dilution integrity RSD value and stability RSD value were less than 3.77 and 7.45%, respectively. Subsequently, the pharmacokinetics were investigated in canine after oral administration of QLNC-3A6 Di-maleate tablets at a dose of 3 mg/kg BW using this method. The results showed that QLNC-3A6 showed fast absorption rate, rapid distribution and slow metabolic elimination in canine plasma. The results of the main PK parameters includingz,,,andwere 0.07 ± 0.01/h, 11.00 ± 2.57 h, 50.88 ± 31.94 ng/mL, 9.08 ± 11.57 h and 836.48 ± 230.53 ng h/mL, respectively.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39625835/